In The News
January 4, 2016
ADVANCE for Hearing & Speech Read the article at www.speech-language-pathology-audiology.advanceweb.com.
Wicked Local Lexington | September 11, 2016
Executives from Lexington-based biotechnology firm Quanterix will present at the Bio Investor Forum, a national conference of technology investors, in October.
Sportsnaut | September 30, 2016
At Powering Precision Health, Robert Stern revealed that Quanterix “has identified elevated levels of tau proteins in blood samples of 96 former football players between 40 and 69 years old, compared with only 25 people of the same age in a control group."
Boston Business Journal | November 21, 2016
Our CEO Kevin Hrusovsky was named one of the Boston Business Journal's 2017 Innovation All-Stars
ScienceDaily | January 6, 2017
Elevated levels of the brain protein tau following concussion are associated with a longer recovery period and may serve as a marker to help physicians determine an athlete's readiness to return to play, report investigators.
News-Medical | February 3, 2017
An interview with Professor David Walt, Tufts University, conducted by April Cashin-Garbutt, MA
USA Today | February 22, 2017
“There will be a lot of major developments when it comes to this research,” Kevin Hrusovsky
Alzforum | April 20, 2017
Tau pathology is linked with neurodegeneration in multiple tauopathies, and efforts are underway to vanquish this tangle-forming protein with anti-tau antibodies.
GenomeWeb| July 18, 2017
NEW YORK (GenomeWeb) – A team of investigators from Quanterix, Destina Genomics, and the University of Edinburgh have developed a new approach for the amplification-free detection of microRNA-122, a biomarker used for diagnosing liver toxicity.
CLP Magazine | September 26, 2017
Quanterix Corp, Lexington, Mass, is expanding its single molecule array, or Simoa, portfolio to include the new Quanterix SR-Plex benchtop instrument.